title: The role of HLA--G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis.
abstract: HLA-G molecules are HLA class Ib antigens characterized by tolerogenic and immunoinhibitory functions. The HLA-G 14-bp insertion/deletion (ins/del) polymorphism controls protein expression and seems to be implicated in both MTX treatment response and SCT outcome. The aim of our study is to evaluate the role of HLA-G 14 bp polymorphism in subjects affected by hematological malignancies undergoing allo-SCT and receiving MTX therapy for GvHD prophylaxis. We performed a retrospective analysis of HLA-G 14 bp polymorphism using a specific PCR in 47 recipients and in their respective donors, and evaluated the correlation with the incidence of aGvHD, OS and disease-free survival (DFS) after allo-SCT. We did not observe any correlation between this polymorphism and the risk of aGvHD occurrence. On the contrary, we found that the recipients with a 14 bp ins/14 bp ins genotype were characterized by a lower OS and DFS in univariate and multivariate analysis (OS=OR: 3.235; DFS=OR: 3.302). These data indicate a role for recipient HLA-G 14 bp polymorphism in allo-SCT immunotolerance status and follow-up.
authors.affiliation: Hematology Department, Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy. p.chiusolo@rm.unicatt.i
authors.forename: P
authors.initials: P
authors.lastname: Chiusolo
authors.forename: S
authors.initials: S
authors.lastname: Bellesi
authors.forename: N
authors.initials: N
authors.lastname: Piccirillo
authors.forename: S
authors.initials: S
authors.lastname: Giammarco
authors.forename: S
authors.initials: S
authors.lastname: Marietti
authors.forename: D
authors.initials: D
authors.lastname: De Ritis
authors.forename: E
authors.initials: E
authors.lastname: Metafuni
authors.forename: M
authors.initials: M
authors.lastname: Stignani
authors.forename: O R
authors.initials: OR
authors.lastname: Baricordi
authors.forename: S
authors.initials: S
authors.lastname: Sica
authors.forename: G
authors.initials: G
authors.lastname: Leone
authors.forename: R
authors.initials: R
authors.lastname: Rizzo
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000235:genetics / Q000401:mortality / Q000517:prevention & control; D059951:HLA-G Antigens / Q000235:genetics*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D054643:INDEL Mutation; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000401:mortality / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D011110:Polymorphism, Genetic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000401:mortality / Q000628:therapy; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D014184:Transplantation, Homologous
chemical_list: D059951:HLA-G Antigens; D007166:Immunosuppressive Agents; D008727:Methotrexate